David Goldblatt is Professor of Vaccinology and Immunology at the Great Ormond Street Institute of Child Health, University College London (UCL) and a Consultant Paediatric Immunologist at the Great Ormond Street Hospital for Children NHS Foundation Trust. He obtained his medical degree from the University of Cape Town, South Africa, a PhD in Immunology from the University of London, United Kingdom. He is an Emeritus National Institute for Health Research (NIHR) Senior Investigator.
He has a long-standing interest in the immune response to vaccines and infectious diseases. He has active research programmes exploring immunity to colonisation/ carriage and infection, correlates of protection and assessing alternative vaccines schedules. His laboratory (a WHO Reference Laboratory for Pneumococcal Serology) interests include Streptococcus Pneumoniae, Klebsiella Pneumonia, Group A and B Streptococcus and SARS-CoV-2. He is an advisor to the World Health Organisation (WHO) on vaccine schedules and Klebsiella Pneumoniae vaccines and chairs the WHO Technical Advisory Group on Group B Streptococcus vaccines. He serves on subcommittees of the United Kingdom Department of Health Joint Committee on Vaccines and Immunisation (JCVI) and advised the MHRA on COVID Vaccine licensure via membership of the Commission on Human Medicines COVID-19 Vaccines Benefit Risk Expert Working Group. He chairs several Scientific Advisory Boards including the International SAB advising the Malawi-Liverpool-Wellcome Trust Clinical Research Programme in Blantyre. He is currently secretary of the International Society of Pneumonia and Pneumococcal Disease having served as President from 2018 to 2024.
